A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
Mené sur 174 patientes atteintes d'un cancer du sein triple négatif de stade précoce (âge médian : 49,5 ans), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité de l'ajout du durvalumab à une chimiothérapie néoadjuvante standard (
Background : Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. Patients and Methods : GeparNuevo is a randomised phase II double-blind placebo-controlled study randomising patients with TNBC to durvalumab or placebo given every 4 weeks in addition to nab-paclitaxel followed by standard EC. In the window-phase durvalumab/placebo alone was given two weeks prior to start of nab-paclitaxel. Randomization was stratified by stromal tumour infiltrating lymphocyte (sTILs). Patients with primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were included. Primary objective was pCR (ypT0 ypN0). Results : A total of 174 patients were randomised, 117 participated in the window-phase. Median age was 49.5 years (range 23-76); 47 patients (27%) were younger than 40 years; 113 (65%) had stage ≥IIA disease, 25 (14%) high sTILs, 138 of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4% (95%CI 42.5%-61.4%) vs placebo 44.2% (95%CI 33.5%-55.3%; unadjusted continuity corrected
χ2P=0.287), corresponding to OR=1.45 (95%CI 0.80-2.63, unadjusted Wald P=0.224). Durvalumab effect was seen only in the window cohort (pCR 61.0% vs 41.4%, OR=2.22, 95%CI 1.06-4.64, P=0.035; interaction P=0.048). In both arms, significantly increased pCR (P<0.01) were observed with higher sTILs. There was a trend for increased pCR rates in PD-L1-positive tumours, which was significant for PD-L1-tumour-cell in durvalumab (P=0.045) and for PD-L1-immune cell in placebo arm (P=0.040). The most common immune-related adverse events were thyroid dysfunction any grade in 47%. Conclusions
:
Our results suggest that the addition of durvalumab to anthracycline/taxane based NACT increases pCR rate particularly in patients treated with durvalumab alone prior to start of chemotherapy.